Efficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patients

AIDS

Volumn 14, Issue 7, 2000, Pages 839-844

  Landau, Alain ^a   Batisse, Dominique ^a   Van Huyen, Jean Paul Duong ^a   Piketty, Christophe ^a   Bloch, Francis ^a   Pialoux, Gilles ^b   Belec, Laurent ^a   Petite, Jean Pierre ^a   Weiss, Laurence ^a   Kazatchkine, Michel D ^a  

^a HÔPITAL BROUSSAIS   (France)

^b HÔPITAL ROTHSCHILD   (France)

Author keywords

Hepatitis C virus; HIV; Interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BUPRENORPHINE; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; METHADONE; PROTEINASE INHIBITOR; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEMOLYSIS; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFLUENZA; IRRITABILITY; LIVER CIRRHOSIS; LYMPHOCYTE COUNT; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SCORING SYSTEM; VIREMIA;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0034065337     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200005050-00010     Document Type: Article

References (28)

1. 1. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko GM, Lee CA. The progression of HCV-associated liver disease in a cohort of haemophiliacs patients. Br J Haematol 1994, 87:555-561.
2. 2. Quan CM, Krajden M, Grigoriew GA, et al. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 1993, 17:117-119.
3. 3. Pialoux G, Landau A, Eliaszewicz M, et al. Rapidly evolving hepatitis-C infection in HIV coinfected patients treated with HAART. 12th World AIDS Conference. Geneva, January 1998 [abstract 22243].
4. 4. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in hemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997, 350:1425-1431.
5. 5. Zylberberg H, Pialoux G, Carnot F, Landau A, Bréchot C, Pol S. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998, 27:1255-1258.
6. 6. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V, et al. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998, 12:1256.
7. 7. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human infected immunodeficiency virus. Clin Infect Dis 1996, 23:585-559.
8. 8. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS 1999, 13:539-546.
9. 9. Reichard O, Norkrans G, Frydén A, et al. Randomised, double blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998, 351:83-87.
10. 10. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assesing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435.
11. 11. Francisci D, Baldelli F, Papili R, et al. Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positive patients. Eur J Epidemiol 1995, 11:123-126.
12. 12. Palela FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
13. 13. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999, 30:1054-1058.
14. 14. Soriano V, Gonzalez J, Pierez Olmeda M, Garcia-Samaniego J. Interferon plus ribavirin for chronic hepatitis C in HIV-patients. Fourth International congress on Drug Therapy in HIV Infection. Glasgow. November 1998 [abstract P299A].
15. 15. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998, 352: 1426-1432.
16. 16. Davies GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998, 339: 1493-1499.
17. 17. Neuville R, Canio JB, Kao J et al. High dose (780 MU: 52 weeks) interferon treatment for chronic hepatitis C: daily induction versus thrice weekly induction therapy. 50th Annual Meeting of the American Association for the Study of Liver Diseases. Dallas. November 1999 [abstract 416].
18. 18. Bonkovsky HL, Stefancyk D, Leclair P, et al. Low doses of ribavirin (600 mg/d) are superior to high doses (1000-1200 mg/ d) with interferon for chronic hepatitis C: result of a controlled randomized, multicenter trial. 50th Annual Meeting of the American Association for the Study of Liver Diseases. Dallas. November 1999 [abstract 418].
19. 19. Boyer N, Marcellin P, Degott C, et al. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992, 165: 723-726.
20. 20. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996, 23:117-125.
21. 21. Mauss S, Klinker A, Ulmer R et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 associated with higher CD4+ cell count. Infection 1998, 261:16-19.
22. 22. Di Bisceglie AM. Hepatitis C. Lancet 1998, 351:351-355.
23. 23. Cribier B, Rey D, Schmitt C, et al. High hepatitis viremia and impaired antibody response in patients coinfected with HIV. AIDS 1995, 9:1131-1136.
24. 24. Nousbaum JB, Pol S, Nalpas B, et al. Characteristics of hepatitis C virus type II (1b) infection in France and Italy. Ann Intern Med 1995, 122:161-168.
25. 25. Munzenberger N, Cassuto JP, Gastaut JA, Souville M, Morin M, Moatti JP. Observance during clinical trials in HIV infection. A discontinuity between patient history and trial logic. Presse Med 1997; 26:358-365.
26. 26. Hoggard PG, Kewn S, Barry MG, et al. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997, 41:1231-1236.
27. 27. Ernstoff MS, Kirkwood JM. Changes in bone marrow of cancer patients treated with recombinant interferon alpha-2b. Am J Med 1984, 76:593-596.
28. 28. Marcellin P, Pouteau M, Gervais A, et al. Long-term histological improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and substained response to interferon-alpha therapy. Ann Intern Med 1997, 127:875-881.